Caplacizumab

CHEMBL2109624 Phase 4 Aprovado Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A nanobody that targets von Willebrand factor to block its interaction with platelets, rapidly reducing the abnormal clotting that defines thrombotic thrombocytopenic purpura. It is used alongside plasma exchange and immunosuppressive therapy for this potentially life-threatening blood disorder. Its nanobody structure provides high specificity with rapid onset of action.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A nanobody that targets von Willebrand factor to block its interaction with platelets, rapidly reducing the abnormal clotting that defines thrombotic thrombocytopenic purpura. It is used alongside plasma exchange and immunosuppressive therapy for this potentially life-threatening blood disorder. Its nanobody structure provides high specificity with rapid onset of action.

Yes, Caplacizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109624. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Procura informações acessíveis para o paciente?

Caplacizumab no PillFYI

Dados Rápidos

Sinônimos: 1

Links Externos

ChEMBL CHEMBL2109624

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.